Can CoRegen’s CRG-150 turn regulatory T cells into a solid tumour weapon?
Find out how CoRegen is advancing CRG-150 into human trials for metastatic breast cancer, prostate cancer and solid tumours.
Pharma & Biotech
Pharma & Biotech
Why the Nona Biosciences and Lonza alliance matters for brain-penetrant biologics
Nona Biosciences and Lonza are building a single-domain antibody platform to cross the blood-brain barrier. Explore the clinical and licensing stakes.